logo

What's Driving The Organic Farming Boom In Thiruvananthapuram?

India.com20-05-2025
Thiruvananthapuram functions as the capital of Kerala state where its population continues its progressive adoption of sustainable agricultural methods because of the city's beautiful landscapes and peaceful backwaters. Organic farming has established itself as a dominant agricultural practice around Thiruvananthapurm because people became more conscious about both their health and environmental sustainability together with increasing consumer need for pesticide-free fruits and vegetables. Organic farming practices continue to grow because of worldwide tendencies together with domestic plans to protect soil quality and improve environmental cleanups and safeguard food accessibility.
Why Organic Farming?
Organic farming blocks the growth of GMOs while preventing the use of synthetic pesticides and utilizing no synthetic fertilizers. The system seeks to preserve environmental stability by implementing crop rotation techniques alongside composting methods along with bio-fertilizer application and pest control done by natural predator systems. Resorts to organic farming occurred around Thiruvananthapuram because of multiple factors influencing this transition.
Today's consumers worry about the potential health problems that come from chemical residue on conventional food. Consumers can find a more beneficial food choice in organic produce.
The traditional farming practices result in ecological damage as well as water pollution because of their methods. The application of organic farming methods leads to healthy soil restoration and protects living species found in nature.
The government through the Paramparagat Krishi Vikas Yojana (PKVY) under India's National Mission for Sustainable Agriculture provides support that motivates farmers to implement organic methods.
The growing organic product market in Thiruvananthapuram urban areas provides farmers with profitable opportunities.
Organic farming takes place in several important areas within the proximity of Thiruvananthapuram
Key Locations Promoting Organic Farming Near Thiruvananthapuram
1. Kerala Agricultural University (KAU), Vellanikkara
KAU operates about 20 kilometers from Thiruvananthapuram to serve as a critical center for promoting organic farming via research work and field training and dissemination programs. The university schedules educational sessions and gives access to information regarding organic farming resources that include vermicompost and biopesticides and green manure for farmers. The practical farming setups on their land operate as operational models to illustrate sustainable agricultural methods for interested learners.
2. Thanal Organic Farming Project
Thanal operates as an NGO from Thiruvananthapuram which began its work in organic farming promotion back in 1990. The agricultural operation maintains a farm outside the city which produces organic plants including vegetables, fruits alongside spices. Thanal operates farmer training programs and uses its advocacy work to campaign for industrial policy improvements favoring organic agricultural operations. Visitors have the opportunity to inspect their facility to experience how traditional wisdom combines modern technology for building sustainable agricultural systems.
3. Pothencode Organic Farmers Market
A weekly organic farmers' market at Pothencode draws in small-scale organic farmers from surrounding villages which reside 15 kilometers toward the east of Thiruvananthapuram. Customers access pesticide-free fresh produce from the producers themselves at this market. This initiative allows local farmers to generate financial benefits and strengthens bonds between farmers and consumers.
4. Attappady Hills Region
Located approximately sixty kilometers away from nearby towns Attappady has earned recognition due to its tribal communities who maintain their practices of traditional organic farming. The indigenous groups keep traditional farming techniques alive across generations which makes them protectors of environmentally friendly farming practices. The process aims to adapt traditional organic farming methods into conventional organic agriculture as an opportunity to enhance farmer well-being.
5. Nedumangad Organic Cluster
Nedumangad serves as a location which nests government-backed organic farm clusters approximately 20 kilometers from Thiruvananthapuram city. The farmers from this area practice organic cultivation of rice alongside vegetables and pepper and cardamom plantation. Through cluster methodology farmers experience collective marketing benefit which results in higher prices for their products.
Challenges Facing Organic Farming
The advantages of organic farming require focus on various obstacles which need resolution:
Small farmers steer clear from organic transformation because organic certification demands both time and financial contributions.
After farmers switch paradigms the first harvests produce lower outputs which stabilizes after the switching period ends.
Many farmers face problems because they do not have access to basic organic farming knowledge combined with technical support about appropriate practices.
The connection between farmers and trustworthy markets continues to pose significant barriers despite available market demand.
Government and Community Initiatives
Several stakeholders function in a joint effort to address these present challenges. For instance:
Krishi Bhavan Centers operate as agricultural extension offices throughout Thiruvananthapram district to supply advice about organic farming alongside subsidies for organic farm products.
Farmer Producer Organizations (FPOs) connect farmers by grouping their produce so they can obtain better market rates from buyers.
Retail chains including Organic Bazaar and online platforms under BigBasket support local farmers by enabling them to secure regular revenue through their organic product sales.
Conclusion
The increasing practice of organic farming around Thiruvananthapuram demonstrates a transition toward ecologically sustainable lifestyles together with consumer responsibility. The movement's continual advantages to environmental health and human health emerge through local farmer support combined with environmentally conscious practices and community participation. Guests can observe organic transformation through their time at Kerala Agricultural University and Thanal projects and at Pothencode's organic market which combines both sightseeing and hands-on participation possibilities. The city of Thiruvananthapuram has the potential to become an example for other urban areas which aim to adopt organic agriculture practices because of its expanding awareness and better infrastructure.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tornado touches down in a Chinese geological park
Tornado touches down in a Chinese geological park

Yahoo

timea minute ago

  • Yahoo

Tornado touches down in a Chinese geological park

STORY: :: August 4, 2025 :: A tornado touches down near a geological park in Inner Mongolia :: Ulanqab, China The footage obtained by Reuters showed clouds swirling above the narrow brown tornado column as the vortex of strong wind gusts sent debris flying everywhere. Reuters was able to verify the location of the footage from the utility tower, building exterior, road layout and terrain which matched file and satellite images. Date of footage was verified by a state media report. No casualties were reported from the incident, according to the state media report.

Market Shifts Toward Targeted Therapies as Advances in Calcium Metabolism Research Drive Development of More Effective Treatments
Market Shifts Toward Targeted Therapies as Advances in Calcium Metabolism Research Drive Development of More Effective Treatments

Yahoo

timea minute ago

  • Yahoo

Market Shifts Toward Targeted Therapies as Advances in Calcium Metabolism Research Drive Development of More Effective Treatments

Calcinosis Cutis is a rare disorder marked by calcium deposits in the skin, often linked to autoimmune diseases like dermatomyositis, systemic sclerosis, and lupus, as well as chronic kidney disease. Symptoms include painful, nodular formations that can lead to complications such as ulcers or restricted movement. Treatment focuses on addressing underlying conditions using phosphate binders, bisphosphonates, or surgery. The market is expanding due to rising autoimmune cases and advances in treatment, despite challenges like high costs and lack of standardized protocols. Key players like Amgen and Pfizer are innovating targeted therapies for better patient outcomes. Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Calcinosis Cutis Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" report has been added to global Calcinosis Cutis market is highly competitive, with several key players driving innovation and market growth. Companies such as Amgen Inc., MediGene Inc., UCB Pharma, Pfizer Inc., AbbVie Inc., Mundipharma, Vertex Pharmaceuticals, and Medtronic are leading the way in developing treatments for calcinosis cutis. These companies are focusing on various treatment approaches, including phosphate binders, biologic agents, and targeted therapies to manage the condition, which is often associated with autoimmune diseases, chronic kidney disease, and metabolic companies are investing in research to better understand the pathophysiology of calcinosis cutis and its connection to underlying diseases like systemic sclerosis and dermatomyositis. With the growing demand for more effective calcium metabolism regulation therapies, these organizations are innovating new solutions that can help slow the progression of the disease, manage symptoms, and improve patient outcomes. As the understanding of calcinosis cutis expands, these players continue to enhance drug development and improve treatment options for affected patients of the key drivers of the calcinosis cutis market is the increasing prevalence of autoimmune diseases, such as scleroderma, dermatomyositis, and lupus, which are strongly associated with the development of calcinosis cutis. As the incidence of these diseases rises, so does the demand for effective treatments for calcium deposits in the skin and soft tissues. Additionally, the growing awareness and diagnostic capabilities around chronic kidney disease and metabolic disorders, which often lead to metastatic calcinosis, are further driving the market. With advancements in treatment options, such as phosphate binders, bisphosphonates, and targeted therapies, there is an increasing demand for solutions to manage calcinosis cutis and improve patient outcomes. The development of personalized and more effective therapies, aimed at addressing the root causes of calcinosis cutis, is also contributing to the growth of the the growth of the Calcinosis Cutis market, several challenges continue to hinder progress. One of the major challenges is the lack of standardized treatment protocols for the condition. Due to the diverse underlying causes of calcinosis cutis, including autoimmune diseases, kidney disorders, and idiopathic cases, there is no one-size-fits-all treatment approach. This complexity makes it difficult for healthcare providers to offer consistent, effective treatments. Additionally, many of the existing therapies, such as bisphosphonates and phosphate binders, have limited effectiveness and may come with side effects, further complicating patient management. Moreover, high treatment costs, particularly for biologic therapies and targeted treatments, pose barriers to accessibility, especially in low-income regions or for patients with limited insurance coverage. The complexity of diagnosis, which often requires a combination of advanced imaging and tissue biopsies, also contributes to delayed diagnosis and intervention, limiting the overall impact of available global calcinosis cutis market is experiencing several key emerging trends. One significant trend is the increased focus on targeted therapies that aim to address the underlying causes of calcium deposition in tissues. Researchers and pharmaceutical companies are developing treatments that target specific mechanisms involved in calcium metabolism and phosphate regulation. This trend is driven by a deeper understanding of the disease's pathophysiology, particularly in relation to autoimmune diseases like scleroderma and dermatomyositis, as well as chronic kidney disease. Targeted therapies, such as phosphate binders, bisphosphonates, and calcification inhibitors, are showing promise in managing the condition more effectively than traditional therapies, offering potential benefits like reduced side effects and improved patient there is a growing interest in the use of combination therapies that can address both the symptoms and the underlying causes of calcinosis, providing a more comprehensive approach to treatment. This shift toward targeted and personalized treatments is expected to drive the next phase of growth in the calcinosis cutis market, enabling more precise and effective management of the Topics Covered:1. Global Calcinosis Cutis Markets: Industry Outlook1.1 Introduction1.2 Market Trends1.3 Regulatory Framework1.4 Epidemiology Analysis1.5 Clinical Trial Analysis1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Challenges1.6.4 Market Opportunities2. Global Calcinosis Cutis Market (Region), ($Million), 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America Calcinosis Cutis Market, by Country2.1.3.1.1 U.S.2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe Calcinosis Cutis Market, by Country2.2.3.1.1 Germany2.2.3.1.2 U.K.2.2.3.1.3 France2.2.3.1.4 Italy2.3 Asia Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia Pacific Calcinosis Cutis Market, by Country2.3.3.1.1 China2.3.3.1.2 Japan2.4 Rest of the World2.4.1 Key Findings2.4.2 Market Dynamics2.4.3 Market Sizing and Forecast3. Global Calcinosis Cutis Market: Competitive Landscape and Company Profiles3.1 Key Strategies and Development3.1.1 Mergers and Acquisitions3.1.2 Synergistic Activities3.1.3 Business Expansions and Funding3.1.4 Product Launches and Approvals3.1.5 Other Activities3.2 Company Profiles3.2.1 Overview3.2.2 Top Products / Product Portfolio3.2.3 Top Competitors3.2.4 Target Customers/End-Users3.2.5 Key Personnel3.2.6 Analyst View Laboratory Corporation of America Holdings Inozyme Pharma, Inc. Medtronic plc Pfizer Inc. Amgen Inc. Vertex Pharmaceuticals UCB Pharma For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

FTSE 100 LIVE: Markets head higher again as earnings season rolls on
FTSE 100 LIVE: Markets head higher again as earnings season rolls on

Yahoo

timea minute ago

  • Yahoo

FTSE 100 LIVE: Markets head higher again as earnings season rolls on

The FTSE 100 (^FTSE) and European stocks gained after the opening bell in London, buoyed for a second day as the recovery from last week's selloff continues and traders digest a slew of corporate earnings. In London, Tuesday morning saw earnings reports from oil major BP (BP.L) and drinks kingpin Diageo (DGE.L) amid a more upbeat mood following a worrying US jobs report on Friday, which missed economists' expectations. Markets are also looking to the Bank of England's next rate-setting meeting on Thursday, where a rate cut is being priced in. The cut would bring interest rates to their lowest levels in two and a half years. London's premier index opened 0.3% higher. Medical equipment manufacturer Smith & Nephew (SN.L) rose the most in the index after announcing a $500m share buyback programme. The more domestically-focused FTSE 250 (^FTMC) was 0.4% higher. The DAX (^GDAXI) in Germany gained 0.7%. Over in France, the CAC 40 (^FCHI) rose 0.4%. Meanwhile the pan-European STOXX 600 (^STOXX) headed 0.4% into the green. Hugo Boss beats Q2 expectations Reuters reported: Here's the BP chart BP reports $2.4bn second-quarter profit Yahoo Finance UK reporter Pedro Goncalves writes: BP (BP.L) reported second-quarter earnings on Tuesday that exceeded analyst expectations, as the oil major seeks to rebuild credibility with investors following a prolonged period of lagging performance relative to its peers. The company posted underlying replacement cost profit — its preferred measure of net income — of $2.35bn for the three months to June, comfortably ahead of the $1.81bn forecast by analysts, according to a consensus compiled by LSEG (LSEG.L). The figure compares with net profit of $2.76bn in the same quarter a year earlier, and $1.38bn in the first three months of 2025. Its quarterly dividend will rise to 8.32 cents from 8 cents and it will keep the pace of its share buyback programme at $750m for the second quarter, it said. The results come amid efforts by BP to regain market confidence, after strategic shifts and leadership changes left shareholders uncertain about the group's long-term direction. Read more on Yahoo Finance UK Palantir stock surges after company reports first billion-dollar quarter From our US team: Palantir (PLTR) stock surged in premarket on Tuesday after the company reported second quarter results that beat analyst estimates across the board as its revenue topped $1 billion in a quarter for the first time. "The growth rate of our business has accelerated radically," Palantir CEO Alex Karp said. "Yet we see no reason to pause, to relent, here." Shares in the defense technology giant were up more than 4% in after-hours trade on Monday. In its second quarter, Palantir posted earnings per share of $0.16, beating consensus estimates of $0.14 and up 77% from the same quarter last year. Revenue came in at $1.004bn, Palantir's first quarter surpassing the billion-dollar mark on a quarterly basis. The company's top line also beat analyst forecasts for $939.25 billion and was up 48% year over year. US commercial revenue came in at $306m, growing 93% year over year, while US government revenue for the quarter was $426m, up 53% from the same quarter last year. Analysts had estimated that sales for the two sectors would come in at $273m and $391m, respectively. Read more on Yahoo Finance Here's the US stock futures chart US stock futures make small gains as Wall Street continues recovery Our US team writes: US stock futures pushed up as Wall Street regained its balance after a tumultuous week and braced for the next wave of corporate earnings. Futures attached to the Dow Jones Industrial Average (YM=F) and the benchmark S&P 500 (ES=F) pushed up 0.2%. while contracts on the Nasdaq 100 (NQ=F) ticked up 0.3%. On Monday, stocks sharply rebounded after tanking on Friday in the aftermath of a number of market-shaking events, including a weak jobs report, fresh tariffs, new signs of rising prices, and the firing of the commissioner of the Bureau of Labor Statistics. President Trump continued to amp up pressure on trade Monday, threatening to hike tariffs on India. Good morning! Hello from London. Lucy Harley-McKeown here, gearing up for another day of news from business and markets. Today we're watching: Quarterly reports from: Oil majors BP (BP.L) and Saudi Aramco ( Drinksmaker Diageo (DGE.L) and housebuilder Travis Perkins (TPK.L) In the US: Mariott (MAR), Pfizer (PFE), Caterpillar (CAT) In data and economic releases: Purchasing managers' indices (PMIs) for services industries from Japan, Asia, the EU, UK and USA UK car sales figures Let's get to it Hugo Boss beats Q2 expectations Reuters reported: Reuters reported: Here's the BP chart BP reports $2.4bn second-quarter profit Yahoo Finance UK reporter Pedro Goncalves writes: BP (BP.L) reported second-quarter earnings on Tuesday that exceeded analyst expectations, as the oil major seeks to rebuild credibility with investors following a prolonged period of lagging performance relative to its peers. The company posted underlying replacement cost profit — its preferred measure of net income — of $2.35bn for the three months to June, comfortably ahead of the $1.81bn forecast by analysts, according to a consensus compiled by LSEG (LSEG.L). The figure compares with net profit of $2.76bn in the same quarter a year earlier, and $1.38bn in the first three months of 2025. Its quarterly dividend will rise to 8.32 cents from 8 cents and it will keep the pace of its share buyback programme at $750m for the second quarter, it said. The results come amid efforts by BP to regain market confidence, after strategic shifts and leadership changes left shareholders uncertain about the group's long-term direction. Read more on Yahoo Finance UK Yahoo Finance UK reporter Pedro Goncalves writes: BP (BP.L) reported second-quarter earnings on Tuesday that exceeded analyst expectations, as the oil major seeks to rebuild credibility with investors following a prolonged period of lagging performance relative to its peers. The company posted underlying replacement cost profit — its preferred measure of net income — of $2.35bn for the three months to June, comfortably ahead of the $1.81bn forecast by analysts, according to a consensus compiled by LSEG (LSEG.L). The figure compares with net profit of $2.76bn in the same quarter a year earlier, and $1.38bn in the first three months of 2025. Its quarterly dividend will rise to 8.32 cents from 8 cents and it will keep the pace of its share buyback programme at $750m for the second quarter, it said. The results come amid efforts by BP to regain market confidence, after strategic shifts and leadership changes left shareholders uncertain about the group's long-term direction. Read more on Yahoo Finance UK Palantir stock surges after company reports first billion-dollar quarter From our US team: Palantir (PLTR) stock surged in premarket on Tuesday after the company reported second quarter results that beat analyst estimates across the board as its revenue topped $1 billion in a quarter for the first time. "The growth rate of our business has accelerated radically," Palantir CEO Alex Karp said. "Yet we see no reason to pause, to relent, here." Shares in the defense technology giant were up more than 4% in after-hours trade on Monday. In its second quarter, Palantir posted earnings per share of $0.16, beating consensus estimates of $0.14 and up 77% from the same quarter last year. Revenue came in at $1.004bn, Palantir's first quarter surpassing the billion-dollar mark on a quarterly basis. The company's top line also beat analyst forecasts for $939.25 billion and was up 48% year over year. US commercial revenue came in at $306m, growing 93% year over year, while US government revenue for the quarter was $426m, up 53% from the same quarter last year. Analysts had estimated that sales for the two sectors would come in at $273m and $391m, respectively. Read more on Yahoo Finance From our US team: Palantir (PLTR) stock surged in premarket on Tuesday after the company reported second quarter results that beat analyst estimates across the board as its revenue topped $1 billion in a quarter for the first time. "The growth rate of our business has accelerated radically," Palantir CEO Alex Karp said. "Yet we see no reason to pause, to relent, here." Shares in the defense technology giant were up more than 4% in after-hours trade on Monday. In its second quarter, Palantir posted earnings per share of $0.16, beating consensus estimates of $0.14 and up 77% from the same quarter last year. Revenue came in at $1.004bn, Palantir's first quarter surpassing the billion-dollar mark on a quarterly basis. The company's top line also beat analyst forecasts for $939.25 billion and was up 48% year over year. US commercial revenue came in at $306m, growing 93% year over year, while US government revenue for the quarter was $426m, up 53% from the same quarter last year. Analysts had estimated that sales for the two sectors would come in at $273m and $391m, respectively. Read more on Yahoo Finance Here's the US stock futures chart US stock futures make small gains as Wall Street continues recovery Our US team writes: US stock futures pushed up as Wall Street regained its balance after a tumultuous week and braced for the next wave of corporate earnings. Futures attached to the Dow Jones Industrial Average (YM=F) and the benchmark S&P 500 (ES=F) pushed up 0.2%. while contracts on the Nasdaq 100 (NQ=F) ticked up 0.3%. On Monday, stocks sharply rebounded after tanking on Friday in the aftermath of a number of market-shaking events, including a weak jobs report, fresh tariffs, new signs of rising prices, and the firing of the commissioner of the Bureau of Labor Statistics. President Trump continued to amp up pressure on trade Monday, threatening to hike tariffs on India. Our US team writes: US stock futures pushed up as Wall Street regained its balance after a tumultuous week and braced for the next wave of corporate earnings. Futures attached to the Dow Jones Industrial Average (YM=F) and the benchmark S&P 500 (ES=F) pushed up 0.2%. while contracts on the Nasdaq 100 (NQ=F) ticked up 0.3%. On Monday, stocks sharply rebounded after tanking on Friday in the aftermath of a number of market-shaking events, including a weak jobs report, fresh tariffs, new signs of rising prices, and the firing of the commissioner of the Bureau of Labor Statistics. President Trump continued to amp up pressure on trade Monday, threatening to hike tariffs on India. Good morning! Hello from London. Lucy Harley-McKeown here, gearing up for another day of news from business and markets. Today we're watching: Quarterly reports from: Oil majors BP (BP.L) and Saudi Aramco ( Drinksmaker Diageo (DGE.L) and housebuilder Travis Perkins (TPK.L) In the US: Mariott (MAR), Pfizer (PFE), Caterpillar (CAT) In data and economic releases: Purchasing managers' indices (PMIs) for services industries from Japan, Asia, the EU, UK and USA UK car sales figures Let's get to it Hello from London. Lucy Harley-McKeown here, gearing up for another day of news from business and markets. Today we're watching: Quarterly reports from: Oil majors BP (BP.L) and Saudi Aramco ( Drinksmaker Diageo (DGE.L) and housebuilder Travis Perkins (TPK.L) In the US: Mariott (MAR), Pfizer (PFE), Caterpillar (CAT) In data and economic releases: Purchasing managers' indices (PMIs) for services industries from Japan, Asia, the EU, UK and USA UK car sales figures Let's get to it Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store